Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21164225 | 0.93 | CYP1A2 (0.38) | CYP2C9CYP1A2CYP19A1CYP2C19CYP2D6 | |
| SCHEMBL22643819 | 0.88 | CYP2C9 (0.39) | CYP2C9CYP1A2CYP19A1CYP2C19CYP2D6 | |
| SCHEMBL9963726 | 0.79 | — | — | |
| SCHEMBL20442226 | 0.76 | CYP1A2 (0.39) | CYP2C9CYP1A2CYP19A1CYP2C19CYP2D6 | |
| SCHEMBL21210844 | 0.76 | CYP1A2 (0.39) | CYP2C9CYP1A2CYP19A1CYP2C19CYP2D6 | |
| SCHEMBL20008446 | 0.76 | CYP1A2 (0.39) | CYP2C9CYP1A2CYP19A1CYP2C19CYP2D6 | |
| SCHEMBL20214851 | 0.76 | CYP1A2 (0.39) | CYP2C9CYP1A2CYP19A1CYP2C19CYP2D6 | |
| SCHEMBL23488073 | 0.72 | PTK2 (0.31) | — | |
| SCHEMBL22535143 | 0.71 | CYP3A4 (0.31) | CYP2C9CYP3A4KMT2A | |
| SCHEMBL25627679 | 0.71 | CYP2C9 (0.38) | CYP2C9CYP1A2CYP19A1CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086735-A1 | N-CYCLOALKYL-N-(BIHETEROCYCLYETHYLENE)-(THIO)CARBOXAMIDE DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086735-A1 | N-CYCLOALKYL-N-(BIHETEROCYCLYETHYLENE)-(THIO)CARBOXAMIDE DERIVATIVES | CBR3, CYP51A1, CBR1 | CYP2C9 17/4885CYP1A2 67/4885CYP19A1 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.